---
document_datetime: 2025-12-29 14:34:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-hydrochlorothiazide-bms.html
document_name: irbesartan-hydrochlorothiazide-bms.html
version: success
processing_time: 0.1027665
conversion_datetime: 2025-12-30 01:33:04.254799
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Irbesartan Hydrochlorothiazide BMS

[RSS](/en/individual-human-medicine.xml/66881)

##### Withdrawn

This medicine's authorisation has been withdrawn

irbesartan / hydrochlorothiazide Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 19 January 2007 the European Commission issued a Marketing Authorisation valid throughout the European Union for the medicinal product Irbesartan Hydrochlorothiazide BMS (irbesartan/hydrochlorothiazide). Irbesartan Hydrochlorothiazide BMS is approved for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone. The marketing authorisation holder (MAH) responsible for Irbesartan Hydrochlorothiazide BMS was Bristol-Myers Squibb Pharma EEIG.

The European Commission was notified by letter dated 20 October 2009 of the MAH's decision to voluntarily withdraw the Marketing Authorisation for Irbesartan Hydrochlorothiazide BMS for commercial reasons. Irbesartan Hydrochlorothiazide BMS has not been marketed anywhere in the European Union and there is no intention to market Irbesartan Hydrochlorothiazide BMS in the future. Irbesartan Hydrochlorothiazide BMS was an informed consent application to Karvezide.

The MAH will maintain the Marketing Authorisation for another medicinal product containing irbesartan/hydrochlorothiazide, i.e. Karvezide. On 11 November 2009 the European Commission issued a decision to withdraw the Marketing Authorisation for Irbesartan Hydrochlorothiazide BMS.

Pursuant to this decision the European Public Assessment Report for Irbesartan Hydrochlorothiazide BMS is updated to reflect that the Marketing Authorisation is no longer valid.

Irbesartan Hydrochlorothiazide BMS : EPAR - Summary for the public

English (EN) (271.32 KB - PDF)

**First published:** 24/11/2009

**Last updated:** 24/11/2009

[View](/en/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-190)

български (BG) (451.13 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/bg/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_bg.pdf)

español (ES) (273.4 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/es/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_es.pdf)

čeština (CS) (410.51 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/cs/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_cs.pdf)

dansk (DA) (273.21 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/da/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_da.pdf)

Deutsch (DE) (273.91 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/de/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_de.pdf)

eesti keel (ET) (271.7 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/et/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_et.pdf)

ελληνικά (EL) (466.09 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/el/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_el.pdf)

français (FR) (274.32 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/fr/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_fr.pdf)

italiano (IT) (272.98 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/it/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_it.pdf)

latviešu valoda (LV) (417.48 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/lv/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (388.93 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/lt/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_lt.pdf)

magyar (HU) (402.11 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/hu/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_hu.pdf)

Malti (MT) (415.65 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/mt/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_mt.pdf)

Nederlands (NL) (273.63 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/nl/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_nl.pdf)

polski (PL) (419.72 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/pl/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_pl.pdf)

português (PT) (273.77 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/pt/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_pt.pdf)

română (RO) (384.8 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/ro/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_ro.pdf)

slovenčina (SK) (408.27 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/sk/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_sk.pdf)

slovenščina (SL) (399.75 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/sl/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_sl.pdf)

Suomi (FI) (272.73 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/fi/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_fi.pdf)

svenska (SV) (272.79 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/sv/documents/overview/irbesartan-hydrochlorothiazide-bms-epar-summary-public_sv.pdf)

## Product information

Irbesartan Hydrochlorothiazide BMS : EPAR - Product Information

English (EN) (1.28 MB - PDF)

**First published:** 24/11/2009

**Last updated:** 24/11/2009

[View](/en/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_en.pdf)

[Other languages (21)](#file-language-dropdown-621)

български (BG) (4.27 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/bg/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_bg.pdf)

español (ES) (1.33 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/es/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_es.pdf)

čeština (CS) (2.67 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/cs/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_cs.pdf)

dansk (DA) (1.29 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/da/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_da.pdf)

Deutsch (DE) (1.38 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/de/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_de.pdf)

eesti keel (ET) (1.29 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/et/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_et.pdf)

ελληνικά (EL) (4.43 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/el/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_el.pdf)

français (FR) (1.38 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/fr/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_fr.pdf)

italiano (IT) (1.32 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/it/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_it.pdf)

latviešu valoda (LV) (3.06 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/lv/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.62 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/lt/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_lt.pdf)

magyar (HU) (2.63 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/hu/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_hu.pdf)

Malti (MT) (2.85 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/mt/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_mt.pdf)

Nederlands (NL) (1.34 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/nl/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_nl.pdf)

polski (PL) (3.05 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/pl/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_pl.pdf)

português (PT) (1.32 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/pt/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_pt.pdf)

română (RO) (1.67 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/ro/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_ro.pdf)

slovenčina (SK) (2.65 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/sk/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_sk.pdf)

slovenščina (SL) (2.56 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/sl/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_sl.pdf)

Suomi (FI) (1.32 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/fi/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_fi.pdf)

svenska (SV) (1.28 MB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/sv/documents/product-information/irbesartan-hydrochlorothiazide-bms-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0030 09/10/2009

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Irbesartan Hydrochlorothiazide BMS : EPAR - All Authorised presentations

English (EN) (251.7 KB - PDF)

**First published:** 24/11/2009

**Last updated:** 24/11/2009

[View](/en/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_en.pdf)

[Other languages (20)](#file-language-dropdown-666)

български (BG) (355.56 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/bg/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_bg.pdf)

español (ES) (251.45 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/es/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_es.pdf)

čeština (CS) (269.12 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/cs/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (251.21 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/da/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (251.34 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/de/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (251.91 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/et/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (356.07 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/el/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_el.pdf)

français (FR) (252.23 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/fr/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (251.95 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/it/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (343.48 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/lv/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (320.39 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/lt/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (299.11 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/hu/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_hu.pdf)

Nederlands (NL) (250.7 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/nl/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_nl.pdf)

polski (PL) (300.75 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/pl/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_pl.pdf)

português (PT) (251.4 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/pt/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_pt.pdf)

română (RO) (317.87 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/ro/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (340.09 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/sk/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (298.32 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/sl/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (251.4 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/fi/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (251.3 KB - PDF)

**First published:**

24/11/2009

**Last updated:**

24/11/2009

[View](/sv/documents/all-authorised-presentations/irbesartan-hydrochlorothiazide-bms-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Irbesartan Hydrochlorothiazide BMS Active substance

- irbesartan
- hydrochlorothiazide

International non-proprietary name (INN) or common name

- irbesartan
- hydrochlorothiazide

Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09DA04

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Treatment of essential hypertension.

## Authorisation details

EMA product number EMEA/H/C/000784 Marketing authorisation holder

Bristol-Myers Squibb Pharma EEIG

Plaza 254 Blanchardstown Corporate Park 2 Dublin 15 D15 T867 Ireland

Marketing authorisation issued 19/01/2007 Withdrawal of marketing authorisation 11/11/2009 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Irbesartan Hydrochlorothiazide BMS : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (284.7 KB - PDF)

**First published:** 24/11/2009

**Last updated:** 24/11/2009

[View](/en/documents/procedural-steps-after/irbesartan-hydrochlorothiazide-bms-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Irbesartan Hydrochlorothiazide BMS : EPAR - Procedural steps taken before authorisation

English (EN) (239.96 KB - PDF)

**First published:** 24/11/2009

**Last updated:** 24/11/2009

[View](/en/documents/procedural-steps/irbesartan-hydrochlorothiazide-bms-epar-procedural-steps-taken-authorisation_en.pdf)

Irbesartan Hydrochlorothiazide BMS : EPAR - Scientific Discussion

English (EN) (253.29 KB - PDF)

**First published:** 24/11/2009

**Last updated:** 24/11/2009

[View](/en/documents/scientific-discussion/irbesartan-hydrochlorothiazide-bms-epar-scientific-discussion_en.pdf)

**This page was last updated on** 24/11/2009

## Share this page

[Back to top](#main-content)